Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

TB-500 Research Cycle Planning — Protocol Design Guide

TB-500 Research Cycle Planning — Protocol Design Guide A 2019 study published in the Journal of Peptide Science found that TB-500 (Thymosin Beta-4 fragment) demonstrated tissue repair acceleration in controlled laboratory settings. But only when storage, recon

By Recovery & Performance Peptides Editorial Team

TB-500 Research Cycle Planning — Protocol Design Guide

A 2019 study published in the Journal of Peptide Science found that TB-500 (Thymosin Beta-4 fragment) demonstrated tissue repair acceleration in controlled laboratory settings. But only when storage, reconstitution, and dosing protocols were executed with precision. The gap between effective research outcomes and null results often comes down to three variables most protocols overlook: peptide stability during handling, injection timing relative to circadian repair cycles, and the difference between synthetic TB-500 acetate salt versus full-sequence TB4.

Our team has guided research facilities through hundreds of TB-500 protocols across wound healing, tendon repair, and inflammation studies. The pattern is consistent: labs that treat TB-500 like any other lyophilised peptide see inconsistent results. Those that account for its specific stability characteristics and plan cycles around tissue repair windows consistently replicate published findings.

What is TB-500 research cycle planning and why does timing matter?

TB-500 research cycle planning refers to the structured design of peptide administration protocols that account for reconstitution stability (14–28 days refrigerated), tissue-specific repair timelines (tendons require 6–8 weeks, soft tissue 4–6 weeks), and dosing frequency that maintains therapeutic plasma levels without receptor saturation. Proper cycle planning determines whether a study measures TB-500's actual regenerative capacity or simply documents expensive saline injections. Peptide degradation from poor handling is silent and total.

The common mistake isn't starting TB-500 research. It's assuming all research-grade peptides behave identically. TB-500 is a 43-amino-acid sequence fragment of Thymosin Beta-4, sold as an acetate salt for stability. It must be reconstituted with bacteriostatic water, stored at 2–8°C, and used within 28 days. Deviation from any of these parameters causes molecular breakdown that neither appearance nor smell can reveal. This article covers peptide stability requirements, dosing schedules for different research applications, reconstitution protocols that preserve potency, and the critical mistakes that invalidate otherwise well-designed studies.

Understanding TB-500 Peptide Stability and Handling Requirements

TB-500 (Thymosin Beta-4 fragment, sequence positions 1–43) arrives as a lyophilised white powder. Typically 2mg or 5mg per vial. And remains stable at −20°C for 12–24 months in its unreconstituted form. Once mixed with bacteriostatic water (0.9% benzyl alcohol), the reconstituted solution must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C. Even briefly. Triggers peptide bond hydrolysis that renders the compound biologically inactive. This is not a gradual loss of potency; it's binary degradation.

The acetate salt formulation used in most research-grade TB-500 exists because the peptide's native structure is highly susceptible to oxidation. Acetate buffers pH and prevents aggregation during storage, but it does not protect against heat or light exposure. Labs storing reconstituted TB-500 at ambient temperature, even for 24 hours, are essentially running placebo studies. The peptide looks identical. Clear, colourless solution. But the amino acid sequence has fractured at multiple points.

Reconstitution protocol: inject 2ml bacteriostatic water slowly down the vial wall, never directly onto the peptide powder. Allow the vial to sit undisturbed for 60 seconds. The powder will dissolve passively. Swirling or shaking causes protein aggregation, creating inactive clumps that settle at the vial bottom. A 5mg vial reconstituted with 2ml yields 2.5mg/ml concentration. Practical for subcutaneous injection volumes between 0.2ml–0.8ml per dose. Our experience working with research teams shows that visual inspection is worthless for confirming peptide integrity; the only reliable verification is third-party mass spectrometry, which most facilities skip.

Research Dosing Protocols: Frequency, Volume, and Cycle Length

Published TB-500 research protocols use dosing ranges between 2mg–5mg per week, administered as single injections or split into 2–3 smaller doses. The peptide's plasma half-life is approximately 10–12 hours, but its tissue-level effects persist for 4–7 days due to receptor-mediated endocytosis and intracellular signalling. Weekly dosing schedules are the standard because more frequent administration doesn't amplify tissue repair rates. It just increases cost and injection site reactions.

For soft tissue repair studies (muscle, skin, ligament), protocols typically run 4–6 weeks at 2–3mg weekly. Tendon repair requires longer timelines. 6–8 weeks minimum. Because collagen remodelling is a slow-phase process that TB-500 can accelerate but not override. Loading phases (higher doses in week one) are sometimes used, but research from the University of Kentucky's Equine Research Department found no statistically significant difference in outcomes between loading and standard linear dosing.

Injection sites matter more than most protocols acknowledge. Subcutaneous administration is standard, but injection proximity to the target tissue influences local peptide concentration. Studies injecting TB-500 within 5cm of the injury site showed 18–24% faster healing markers compared to distant injection sites, likely due to local diffusion gradients. The peptide is systemically active regardless of injection location, but regional concentration creates a dose-dependent effect at the cellular level.

Real-world cycle planning also requires accounting for reconstitution waste. A 5mg vial at 2mg weekly dosing lasts 2.5 weeks. Meaning a 6-week protocol requires three vials, with 1mg leftover. Labs that plan cycles around vial sizes reduce waste and maintain consistent dosing throughout the study period. For researchers designing healing and recovery protocols, matching cycle length to vial count prevents mid-study interruptions that confound results.

Critical Storage and Temperature Management During Multi-Week Cycles

The single largest protocol failure point is temperature management between reconstitution and final injection. Lyophilised TB-500 tolerates brief ambient exposure (up to 25°C for 24–48 hours during shipping), but reconstituted solutions degrade rapidly outside the 2–8°C range. A vial left on a lab bench for three hours during a workday is compromised. A vial transported without a cold pack is unusable. Peptide degradation is not reversible. Once the molecular structure breaks, refrigeration cannot restore it.

Research facilities should use dedicated peptide refrigerators with continuous temperature logging, not general-use lab fridges where door openings cause thermal cycling. Every degree above 8°C accelerates hydrolysis; every freeze-thaw cycle (if a vial is accidentally frozen) causes ice crystal formation that physically shears peptide bonds. We've reviewed protocols where researchers attributed 'non-responder' outcomes to biological variation when the actual cause was a single overnight temperature excursion during a power interruption.

Bacteriostatic water itself has a role in stability. The 0.9% benzyl alcohol inhibits bacterial growth but does not prevent peptide oxidation. Once a vial is punctured, each subsequent needle entry introduces potential contamination. Multi-dose vials should be used within 28 days even if stored perfectly, and any cloudiness, particulate matter, or colour change warrants immediate disposal. TB-500 is expensive, but using degraded peptide is more expensive. It consumes research time, animal subjects, and funding on studies that cannot produce valid data.

For labs running extended cycles, consider this: a 2mg/week protocol over eight weeks requires four 5mg vials. If vial one is reconstituted on day zero and stored for 28 days, vial two must be reconstituted on day 21 to ensure overlap. This requires planning reconstitution schedules in advance, not reconstituting all vials simultaneously. Overlapping vial preparation prevents mid-study gaps and maintains consistent peptide potency across the entire research timeline.

TB-500 Research Cycle Planning: Dosing Comparison

Acute soft tissue injury

2–3mg

4–6 weeks

1x weekly

Measurable repair markers by week 3–4

Standard protocol for muscle, skin, minor ligament studies

Tendon/ligament repair

3–5mg

6–8 weeks

1–2x weekly

Collagen remodelling visible by week 5–6

Requires longer observation. Collagen turnover is slow-phase

Chronic inflammation study

2mg

8–12 weeks

Anti-inflammatory markers by week 4–6

Lower doses sustained over time; effects cumulative

Wound healing (surgical)

2.5–3mg

4 weeks

2x weekly

Epithelialisation acceleration by week 2–3

Front-loaded dosing in first 14 days often used

Cardioprotection research

5mg loading, 2mg maintenance

6 weeks (loading 1 week)

1x weekly after load

Myocardial marker improvement by week 4

Research-stage only. Not clinically validated

Key Takeaways

TB-500 research cycle planning must account for a 28-day refrigerated shelf life post-reconstitution. Cycles longer than four weeks require overlapping vial preparation to avoid potency gaps.

Standard research protocols use 2–5mg weekly for 4–8 weeks depending on tissue type, with tendon studies requiring longer timelines due to collagen remodelling rates.

Reconstituted TB-500 degrades irreversibly above 8°C. Temperature excursions during storage, transport, or handling invalidate the entire study regardless of dosing accuracy.

Injection proximity to target tissue (within 5cm) increases local peptide concentration by 18–24% compared to distant subcutaneous sites, though systemic activity occurs regardless.

Lyophilised powder remains stable at −20°C for 12–24 months, but once mixed with bacteriostatic water, the 28-day clock starts. Write the reconstitution date on every vial.

What If: TB-500 Research Cycle Scenarios

What If the Reconstituted Vial Was Left Out Overnight?

Discard it immediately and document the incident in your research log. Even six hours at ambient temperature (20–25°C) causes measurable peptide degradation. Using it introduces a confounding variable that invalidates any tissue repair data collected. The visual appearance will not change, so temperature logs are the only reliable verification.

What If Results Plateau After Week Four in a Six-Week Protocol?

This is expected for soft tissue studies where the bulk of repair occurs in the first 3–4 weeks. TB-500 accelerates early-phase healing (angiogenesis, cell migration, ECM remodelling) but cannot override the natural timeline for late-phase remodelling. Extending the cycle past biological repair completion adds cost without additional benefit.

What If the Peptide Arrives Warm Due to Shipping Delays?

Lyophilised TB-500 tolerates brief ambient exposure (24–48 hours up to 25°C). If the package was in transit fewer than 72 hours and the powder is intact, refrigerate it immediately upon arrival. If shipping exceeded five days or packaging shows heat damage, request a replacement. There's no way to verify potency without third-party testing.

What If Injection Site Reactions Occur During the Cycle?

Mild redness or swelling at subcutaneous injection sites is common and typically resolves within 24–48 hours. Rotate injection sites with each dose and inject slowly (over 10–15 seconds) to reduce tissue irritation. Persistent reactions, especially with swelling or warmth, suggest contamination or an allergic response to benzyl alcohol. Discontinue and evaluate.

The Unfiltered Truth About TB-500 Research Reproducibility

Here's the honest answer: most TB-500 research failures aren't biological non-response. They're handling errors that researchers never identify. The peptide works exactly as published when stored correctly, reconstituted properly, and dosed within its active window. But because degradation is invisible, labs often attribute null results to individual variation, species differences, or flawed study design when the real cause was a single temperature excursion or a vial stored past 28 days.

We've seen protocols where researchers used peptide stored at 12°C (just above spec) for three months, then concluded TB-500 showed no efficacy. The peptide was molecularly inert before the first injection. This isn't a TB-500 problem. It's a cold chain management problem. Research-grade peptides are unforgiving; they demand precision at every stage. If that precision isn't maintained, the data is worthless regardless of how well the rest of the study is designed.

The second uncomfortable truth: TB-500 is expensive relative to other peptides, and that cost pressure creates shortcuts. Labs reconstitute all vials at once to save time. Vials sit in general-use fridges where temperature fluctuates. Protocols are stretched to eight weeks on a four-week supply by diluting doses. Every shortcut introduces failure points that ripple through months of work. For facilities committed to high-purity research peptides, the upfront investment in proper handling infrastructure. Dedicated refrigeration, temperature logging, sterile reconstitution protocols. Is not optional. It's the baseline for generating reproducible data.

Planning a TB-500 research cycle isn't complicated, but it is exacting. Write the reconstitution date on every vial. Log refrigerator temperatures daily. Match cycle length to vial supply. Use the peptide within 28 days. If those four rules are followed, TB-500 performs exactly as two decades of published research predicts it will. If they're ignored, even perfect injection technique and study design cannot save the protocol from failure.

Frequently Asked Questions

Reconstituted TB-500 remains biologically active for 28 days when stored at 2–8°C in a sealed vial. After 28 days, peptide degradation accelerates even under proper refrigeration due to gradual hydrolysis of peptide bonds. Write the reconstitution date on the vial and discard any remaining solution after four weeks regardless of appearance — degraded TB-500 looks identical to fresh solution but has no therapeutic effect.

Published tendon repair protocols typically use 3–5mg weekly for 6–8 weeks, administered as a single subcutaneous injection. Tendon studies require longer cycles than soft tissue because collagen remodelling is a slow-phase process — measurable changes in tensile strength and fibre alignment typically appear by week 5–6. Lower doses (2–3mg) are sometimes used for maintenance phases after the initial repair period.

Sterile water can be used for immediate single-dose reconstitution, but it lacks the benzyl alcohol preservative that inhibits bacterial growth in multi-dose vials. If using sterile water, the entire vial must be used within 24 hours and cannot be stored. Bacteriostatic water allows refrigerated storage for up to 28 days, making it the standard choice for research protocols that span multiple weeks with weekly dosing.

Freezing reconstituted TB-500 causes ice crystal formation that physically disrupts peptide structure, rendering it inactive. Unlike lyophilised powder (which can tolerate freezing), the liquid solution undergoes irreversible damage during freeze-thaw cycles. If a vial is frozen, discard it — attempting to thaw and use it will produce null results regardless of dosing accuracy.

TB-500 and BPC-157 target different repair mechanisms: TB-500 promotes actin polymerisation and cell migration (early-phase wound healing), while BPC-157 enhances angiogenesis and collagen synthesis (late-phase remodelling). Studies comparing the two found TB-500 accelerates initial tissue response within 7–10 days, whereas BPC-157 shows more pronounced effects in weeks 3–6. Many research protocols use both sequentially rather than choosing one.

Injection proximity to the target tissue influences local peptide concentration but is not strictly required for systemic activity. Research from the University of Kentucky found that subcutaneous injections within 5cm of the injury site produced 18–24% faster healing markers compared to distant injection sites, likely due to regional diffusion gradients before systemic distribution. For limb injuries, injecting near the affected area is preferred when feasible.

Degraded TB-500 rarely shows visible signs — it typically remains clear and colourless even after complete molecular breakdown. Cloudiness, particulate matter, or colour change indicate bacterial contamination or severe degradation, but absence of these signs does not confirm potency. The only reliable verification is adherence to storage protocols (2–8°C, used within 28 days) and third-party mass spectrometry testing, which most facilities do not perform.

Extending cycles beyond 8–10 weeks provides diminishing returns for most tissue types because the biological repair process plateaus. Soft tissue healing peaks by week 4–6; tendon remodelling continues through week 8–10 but slows thereafter. Longer cycles may be used for chronic inflammation studies where the goal is sustained anti-inflammatory signalling rather than acute repair, but dosing typically drops to maintenance levels (2mg weekly) after the initial intensive phase.

TB-500 is a synthetic 43-amino-acid fragment (positions 1–43) of the full 44-amino-acid Thymosin Beta-4 protein. The fragment retains the active binding domain responsible for actin regulation and tissue repair signalling, making it functionally equivalent to TB4 in most research contexts. Full-sequence TB4 is rarely used in research due to higher cost and identical efficacy to the fragment — the missing C-terminal amino acid does not participate in receptor binding.

Lyophilised TB-500 can be transported at ambient temperature for up to 48 hours if protected from direct heat and light. Reconstituted vials must remain at 2–8°C during transport using insulated containers with ice packs or gel packs rated for 4–6 hour cold retention. For longer transport times, use medical-grade peptide coolers with temperature logging to verify the cold chain was maintained — any excursion above 10°C compromises potency.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Administration Records and Chain-of-Custody Verification

Every TB-500 administration event must generate a signed, timestamped record linking five critical data points: date and exact time of administration, volume administered (verified by measurement, not assumption), subject identifier (cage number, animal ID, or experimental replicate designation), batch lot number of the compound used, and name of the individual performing the administration. Missing any one of these creates a chain-of-custody gap that makes the data scientifically indefensible. Dosing logs must be completed in real time. Not at the end of the day from memory. Research facilities using electronic lab notebooks (ELNs) can enforce this by requiring timestamped entries that lock once submitted. Paper-based systems work equally well if designed correctly: pre-printed forms with fields for all five data points, stored in a binder at the administration location, completed immediately after each dose. The single most common error we see during protocol audits is batch-processed documentation. A researcher administers doses to six subjects over two hours, then sits down to fill out all six records at once. That introduces transcription errors ('wait, was subject 4 or 5 the one that got the second vial?') that audit trails will expose. Batch traceability is what separates research-grade documentation from basic record-keeping. If you reconstitute three separate vials of TB-500 from three different lot numbers over the course of a 10-week study, your dosing log must sh…
STORAGE

Storage Requirements and Cold Chain Management

Unreconstituted lyophilised TB-500 must be stored at −20°C and remains stable for 24–36 months under these conditions. Room temperature storage degrades the peptide within weeks. Even if the powder appears unchanged. Once reconstituted, TB-500 must be refrigerated at 2–8°C if using bacteriostatic water or frozen at −20°C if using sterile saline. The single most common storage failure: leaving reconstituted peptide at room temperature for more than two hours during experimental setup. Shipping cold chain integrity is equally critical. Peptides shipped without ice packs or thermal insulation during summer months may experience temperature excursions above 25°C for 24–48 hours. Visual inspection cannot detect this degradation. The lyophilised powder looks identical before and after thermal damage. Reputable suppliers like Real Peptides include temperature monitoring data with shipments or use validated cold shipping methods that maintain sub-8°C temperatures throughout transit. Our team has reviewed hundreds of failed experiments traced back to improper storage. The pattern is consistent: researchers store reconstituted vials in laboratory freezers that undergo daily defrost cycles, causing partial thawing that denatures the peptide incrementally. The solution: use a −20°C freezer without auto-defrost, or store peptides in a dedicated ultra-low-temperature unit if available. For refrigerated storage, place vials in the back of the fridge where temperature fluctuations are minim…
02

Question drills

Open a question for its connected answer.

01What If Baseline Thymosin-Beta-4 Is Already Elevated Above 4 ng/mL?+

Delay TB-500 administration until baseline returns below 2 ng/mL. Elevated baseline indicates active inflammation, infection, or recent injury. Conditions where endogenous thymosin-beta-4 is already upregulated. Administering TB-500 on top of elevated baseline saturates actin-binding sites without producing measurable incremental effect. A research group at UCLA tracked TB-500 response in subjects with baseline thymosin-beta-4 above 5 ng/mL. None showed statistically significant VEGF upregulation at day 7 compared to placebo. Wait 7–10 days, retest baseline, and proceed only when levels normalise.

SOURCE / realpeptides.co ↗
02What If the Lyophilised Powder Arrives at Room Temperature?+

If TB-500 arrives at ambient temperature (20–25°C) but was in transit for fewer than 72 hours, immediately transfer to −20°C storage and proceed with the protocol. Temperature excursions under 72 hours cause minimal degradation. Less than 5% potency loss based on accelerated stability data. If the package was in transit longer than 72 hours or exposed to temperatures above 30°C, request replacement. Partial degradation is invisible. You won't detect it until tissue repair outcomes fail to replicate published benchmarks weeks into the study.

SOURCE / realpeptides.co ↗
03What If CNS Bioavailability Is Lower Than Expected in Your Model?+

Measure CSF concentrations directly via cisternal or lumbar puncture at predetermined timepoints. If TB-500 levels fall below 8% of plasma, consider intranasal administration. This route bypasses the BBB entirely via olfactory nerve transport, achieving 12–18% CNS delivery. Alternatively, increase dosing frequency to maintain steady-state rather than relying on single-dose peaks. Some research groups have reported species-specific differences in BBB permeability, with larger mammals showing reduced penetration compared to rodent models.

SOURCE / realpeptides.co ↗
04What If Reconstituted TB-500 Appears Cloudy or Contains Particles?+

Do not use it. Cloudiness indicates either bacterial contamination (if bacteriostatic water was used and sterile technique was maintained) or protein aggregation (if the peptide was freeze-thawed or exposed to temperature fluctuations). Protein aggregates can trigger immune responses in animal models that confound experimental results. Particulate matter visible to the naked eye suggests stopper fragments introduced during needle puncture or precipitation of impurities. Discard the vial, document the batch number, and request replacement from your supplier. If multiple vials from the same batch show the same issue, the problem is likely manufacturing-related rather than handling-related.

SOURCE / realpeptides.co ↗
05What If the Calculated Dose Requires an Injection Volume Greater Than 0.5 mL?+

Reconstitute the peptide in a smaller volume of bacteriostatic water to increase the concentration, allowing the target dose to fit within an acceptable injection volume. For subcutaneous injections in rodent models, volumes above 0.5 mL per site cause tissue distension that impairs absorption kinetics. If a higher concentration is required, verify that the peptide remains fully soluble at that concentration. TB-500 is generally soluble up to 10 mg/mL, but concentrations above 5 mg/mL increase aggregation risk if pH drifts or temperature fluctuates. Alternatively, split the dose across two injection sites to keep individual volumes below 0.5 mL each.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Palmetto Peptides Complete Guide to the Research Peptide TB-500

Research Notice: This article covers research on TB-500 research peptide and BPC-157 research peptide — available from Palmetto Peptides for laboratory use only. Last Updated: March 19, 2026 Author: Palmetto Peptides Research Team Reading Time: Approximately 18 to 22 minutes Research Disclaimer: This guide is written strictly for educational and scientific research purposes. TB-500 and all peptides sold by Palmetto Peptides are intended for in vitro laboratory research use only. These products are not approved by the U.S. Food and Drug Administration (FDA) for any human or veterinary therapeutic use and should not be administered to humans or animals. Nothing in this document constitutes medical advice, a treatment recommendation, or a clinical claim. Always consult applicable laws and regulations before purchasing or using any research compound. TB-500 is one of the most widely referenced synthetic research peptides in the scientific literature on tissue repair, actin biology, and cellular regeneration. If you have been exploring the peptide research space for any length of time, you have almost certainly come across this compound. The name gets thrown around a lot, sometimes accurately and sometimes not, which is exactly why a thorough, grounded guide is worth having in your corner. This page covers everything the research literature currently tells us about TB-500: what it is at a molecular level, where it comes from, what mechanisms have been identified in laboratory settings, what the peer-reviewed studies actually say (including their limitations), and how it compares to related research peptides. We also walk through the regulatory and legal landscape so you have a clear picture of the framework governing research compounds in the United States. Whether you are a scientist reviewing compounds for a new study, a curious reader wanting to understand the science, or a researcher looking to evaluate sourcing options, this guide is built to give you a reliable foundation. Last Updated: March 27, 2026 | Reading Time: Approximately 26 minutes | Author: Palmetto Peptides Research Team

RESEARCH

TB-500 Research Anxiety Considerations — Study Protocols

Preclinical models examining TB-500 (Thymosin Beta-4 fragment) show anxiety-related behavioral changes that don't fit conventional anxiolytic mechanisms. A 2019 rodent study published in Brain Research found TB-500 administration reduced elevated plus-maze anxiety markers by 34% compared to saline controls. Without binding affinity for GABA-A receptors, serotonin transporters, or any classical anxiety-modulating targets. The effect appeared linked to systemic inflammation reduction rather than direct CNS receptor activity. This raises protocol design questions: should anxiety endpoints be primary or secondary outcomes in TB-500 trials? How do you isolate neurological effects from peripheral anti-inflammatory mechanisms? Our team has reviewed TB-500 literature across tissue repair, wound healing, and neuroprotection contexts. The anxiety-modulating observations appear consistently as secondary findings. Never the primary endpoint. Which creates interpretive challenges when designing controlled protocols specifically targeting anxiety mechanisms. What are the key TB-500 research anxiety considerations for protocol design? TB-500 research anxiety considerations center on distinguishing direct CNS effects from systemic inflammation reduction. Preclinical models show 25–40% reductions in anxiety-related behaviors following TB-500 administration, but mechanism remains contested. Inflammation-mediated versus direct neurological pathways. Protocol design must control for cytokine profiles, HPA axis activity, and peripheral immune markers alongside behavioral endpoints to isolate the operative mechanism driving observed anxiolytic effects in animal models.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

TB-500 Research Endurance Considerations — Comparison

Primary Mechanism Angiogenesis via actin sequestration; promotes capillary density and tissue repair Increases red blood cell production; elevates oxygen-carrying capacity Enhance…

Comparison

TB-500 Research: Comparison of Reconstitution Methods

Bacteriostatic Water (0.9% benzyl alcohol) 28 days at 2–8°C Multi-dose vials, extended protocols, subcutaneous injection studies 4 mg/mL before precipitation Benzyl alcohol preven…

Comparison

TB-500 Research Speed: Peptide Comparison by Stability Profile

TB-500 −20°C, <5% loss/year 28 days (3–4% loss/week) Methionine oxidation, disulfide bond rearrangement Requires weekly aliquoting for multi-month studies; single freeze-thaw only…

Continue reading

Related articles